Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/28901
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lordick F. | en |
dc.contributor.author | Chen L.-T. | en |
dc.contributor.author | Barbour A. | en |
dc.contributor.author | Tebbutt N. | en |
dc.contributor.author | Price T. | en |
dc.contributor.author | Roy A.C. | en |
dc.contributor.author | Shapiro J. | en |
dc.contributor.author | Burge M. | en |
dc.contributor.author | Karapetis C.S. | en |
dc.contributor.author | Pavlakis N. | en |
dc.contributor.author | Segelov E. | en |
dc.contributor.author | Chau I. | en |
dc.date.accessioned | 2021-05-14T09:44:29Z | en |
dc.date.available | 2021-05-14T09:44:29Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20200502 | en |
dc.date.issued | 2020-05-02 | en |
dc.identifier.citation | Expert Review of Anticancer Therapy. 20 (4) (pp 305-324), 2020. Date of Publication: 02 Apr 2020. | en |
dc.identifier.issn | 1473-7140 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/28901 | en |
dc.description.abstract | Introduction: A multimodal approach in operable early-stage oesophago-gastric (OG) cancer has evolved in the last decade, leading to improvement in overall outcomes. Areas covered: A review of the published literature and conference abstracts was undertaken on the topic of optimal adjunctive chemotherapy or chemoradiotherapy in early-stage OG cancers. This review article focuses on the current evidence pertaining to neoadjuvant and perioperative strategies in curable OG cancers including the evolving landscape of immunotherapy and targeted drugs in this setting. Expert commentary: Adjunctive therapies in the form of preoperative chemo-radiotherapy (CRT) or chemotherapy and perioperative chemotherapy over surgery alone improve outcomes in patients with operable OG cancer. Although there are variations in practice around the world, a multi-disciplinary approach to patient care is of paramount importance. Immunotherapy and on treatment functional imaging are two examples of emerging strategies to improve the outcome for early-stage patients. A better understanding of the molecular biology of this disease may help overcome the problem of tumor heterogeneity and enable more rationally designed and targeted therapeutic interventions in the future.Copyright © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Taylor and Francis Ltd | en |
dc.relation.ispartof | Expert Review of Anticancer Therapy | en |
dc.subject.mesh | stomach cancer | - |
dc.subject.mesh | bevacizumab/ct | - |
dc.subject.mesh | bevacizumab | - |
dc.subject.mesh | capecitabine/ct | - |
dc.subject.mesh | capecitabine | - |
dc.subject.mesh | carboplatin/ct | - |
dc.subject.mesh | carboplatin | - |
dc.subject.mesh | cisplatin/ct | - |
dc.subject.mesh | cisplatin | - |
dc.subject.mesh | docetaxel/ct | - |
dc.subject.mesh | docetaxel | - |
dc.subject.mesh | epirubicin/ct | - |
dc.subject.mesh | epirubicin | - |
dc.subject.mesh | fluorouracil/ct | - |
dc.subject.mesh | fluorouracil | - |
dc.subject.mesh | gimeracil plus oteracil potassium plus tegafur/ct | - |
dc.subject.mesh | gimeracil plus oteracil potassium plus tegafur | - |
dc.subject.mesh | oxaliplatin/ct | - |
dc.subject.mesh | oxaliplatin | - |
dc.subject.mesh | paclitaxel/ct | - |
dc.subject.mesh | paclitaxel | - |
dc.subject.mesh | vinorelbine tartrate/ct | - |
dc.subject.mesh | vinorelbine tartrate | - |
dc.subject.mesh | gastroesophageal cancer | - |
dc.subject.mesh | oxaliplatin | - |
dc.subject.mesh | cancer adjuvant therapy | - |
dc.subject.mesh | cancer immunotherapy | - |
dc.subject.mesh | cancer staging | - |
dc.subject.mesh | cancer surgery | - |
dc.subject.mesh | chemoradiotherapy | - |
dc.subject.mesh | computer assisted tomography | - |
dc.subject.mesh | endoscopic ultrasonography | - |
dc.subject.mesh | esophageal squamous cell carcinoma | - |
dc.subject.mesh | esophagus cancer | - |
dc.subject.mesh | external beam radiotherapy | - |
dc.subject.mesh | geography | - |
dc.subject.mesh | multimodality cancer therapy | - |
dc.subject.mesh | multiple cycle treatment | - |
dc.subject.mesh | patient care | - |
dc.subject.mesh | patient selection | - |
dc.subject.mesh | perioperative period | - |
dc.subject.mesh | stomach cancer | - |
dc.title | Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. | en |
dc.type | Review | en |
dc.identifier.affiliation | Oncology | - |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/14737140.2020.1746185 | - |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 32202178 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32202178] | en |
dc.identifier.source | 2004690522 | en |
dc.identifier.institution | (Roy, Karapetis) Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Australia (Shapiro) Cabrini Health, Monash University, Melbourne, Australia (Burge) Department of Cancer Care Services, Royal Brisbane Hospital, University Of Queensland, Herston, Australia (Pavlakis) Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia (Segelov) Department of Medical Oncology, Monash University and Monash Health, Melbourne, Australia (Chau) Department of Medical Oncology, Royal Marsden Hospital, Institute of Cancer Research, Surrey, London, United Kingdom (Lordick) Leipzig University Medical Centre, University Cancer Centre Leipzig, Leipzig, Germany (Chen) National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan (Republic of China) (Barbour) The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia (Tebbutt) Department of Medical Oncology, Austin Health, Heidelberg, Australia (Price) Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia | en |
dc.description.address | A.C. Roy, Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, SA 5042, Australia. E-mail: amitesh.roy@sa.gov.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | adjuvant chemotherapy Gastric oesophageal peri operative | en |
dc.identifier.authoremail | Roy A.C.; amitesh.roy@sa.gov.au | en |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairetype | Review | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.